# Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

> **NCT07487168** · PHASE1 · NOT_YET_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 24 (estimated)

## Conditions studied

- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** Mitomycin C (MMC)
- **DEVICE:** Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)

## Key facts

- **NCT ID:** NCT07487168
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07487168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07487168, "Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07487168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*